Follow our progress

LONDON and RALEIGH, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at…

Strengthens financial flexibility to support the Company’s continued growth LONDON and RALEIGH, N.C., Jan. 02, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces it and its…

LONDON and RALEIGH, N.C., Nov. 17, 2023 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces its President and CEO, David Zaccardelli, has won ‘Executive…

LONDON and RALEIGH, N.C., Nov. 08, 2023 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at…

US FDA accepted NDA filing for ensifentrine for maintenance treatment of COPD PDUFA Target Action Date of June 26, 2024 Commercial launch preparations supported by strong balance sheet Conference call…

LONDON and RALEIGH, N.C., Oct. 19, 2023 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that…

LONDON and RALEIGH, N.C., Oct. 06, 2023 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces it will hold an Investor Update in New York City for investors and analysts on Wednesday, October 18, 2023, from 8:00 – 10:00 AM ET.

PDUFA Target Action Date of June 26, 2024 Pooled analysis and subgroup data further support potential of ensifentrine, an investigational, novel, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH,…

PDUFA Target Action Date of June 26, 2024 Ensifentrine, if approved, is expected to be the first novel mechanism available for the maintenance treatment of COPD in more than a…